Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in prion immunotherapy.

Frank L Heppner1, Adriano Aguzzi

  • 1Institute of Neuropathology, University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Switzerland. frank.heppner@usz.ch

Current Opinion in Immunology
|September 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gpnmb defines a phagocytic state of microglia linked to cell death in prion disease mouse model.

Nature communications·2026
Same author

Altered crosstalk of bacterial lipopolysaccharide with immune cells in colorectal cancer compared to paired adjacent intestinal tissue.

Gut microbes·2026
Same author

Prion propagation is controlled by a hierarchical network involving the nuclear Tfap2c and hnRNP K factors and the cytosolic mTORC1 complex.

PLoS pathogens·2026
Same author

Large-scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation.

FEBS open bio·2026
Same author

Structure-function relationship of alpha-synuclein fibrillar polymorphs derived from distinct synucleinopathies.

Molecular systems biology·2026
Same author

Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes.

bioRxiv : the preprint server for biology·2026
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
Same journal

On or within: spatial determinants of antigen handling in the nasal turbinates.

Current opinion in immunology·2026
Same journal

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
Same journal

Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection.

Current opinion in immunology·2026
See all related articles

Antibody immunotherapy shows promise for prion diseases by targeting the cellular prion protein (PrPC). Overcoming immune tolerance to PrPC is key to developing effective treatments against prion infections.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Prion diseases are fatal neurodegenerative disorders.
  • Antibody-based immunotherapy targeting the cellular prion protein (PrPC) shows potential against prion diseases.
  • Host tolerance to endogenous PrPC hinders the induction of protective immune responses.

Purpose of the Study:

  • To investigate the challenges and potential strategies for inducing immune responses against native cell-surface PrPC.
  • To explore the feasibility of antibody-based immunotherapy for prion diseases.

Main Methods:

  • Review of existing studies on antibody-based immunotherapy against prion proteins.
  • Analysis of challenges in overcoming immune tolerance to PrPC.
  • Discussion of B cell intrinsic factors and T helper cell tolerance.

Related Experiment Videos

Main Results:

  • Antibodies to PrPC can antagonize prion protein (PrPSc) deposition in vitro and in vivo.
  • Inducing immune responses to recombinant PrP is feasible but difficult to achieve for native cell-surface PrPC.
  • Peripheral T helper tolerance may impede the development of effective anti-PrPC antibodies.

Conclusions:

  • Antibody-based immunotherapy is a potential strategy for prion diseases.
  • Overcoming immune tolerance to PrPC is crucial for therapeutic development.
  • Further research is needed to elicit immune responses against native PrPC for effective prion disease treatment.